Savara prices $130M equity at $4.20

6 hours ago 1

Clinical stage biopharmaceutical company focused on rare respiratory diseases—Savara (SVRA) priced an underwritten public offering of ~23.81M shares at a price of $4.20 per share.
Total gross proceeds of $130M are expected
The underwriters have a 30-day option to purchase up